Verbascum Thapsus Whole

Dosage for Verbascum Thapsus Whole is highly individualized and is determined by the patient's sensitivity level, as measured by skin testing. There is no 'one-size-fits-all' dose.

Diagnostic Dosing

• Skin Prick Test (SPT): Usually performed using a 1:10 or 1:20 w/v glycerinated extract. A single drop is applied to the skin, followed by a puncture. Results are read at 15–20 minutes.
• Intradermal Test: If SPT is negative, an intradermal injection of 0.02 mL to 0.05 mL of a more dilute aqueous extract (e.g., 1:1000 w/v) may be administered.

Immunotherapy Dosing (SCIT)

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are typically given 1–2 times per week, with the dose increasing by 50% to 100% each time, provided no significant local reactions occur.
• Maintenance Phase: Once the 'Top Dose' or 'Maintenance Dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v concentration), the interval between injections is increased to every 2–4 weeks. This phase usually lasts 3 to 5 years.

Verbascum Thapsus Whole is generally considered safe for use in children, typically starting at age 5. Dosing protocols for children are similar to adult protocols, though the starting concentration may be even more dilute depending on the child's history of asthma or severe allergies. Clinical data suggests that early intervention with immunotherapy in children may prevent the development of new sensitivities (the 'allergic march'). However, use in children under age 5 requires extreme caution due to the difficulty of the child communicating early symptoms of systemic reactions.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment, as the allergenic proteins are not cleared via the kidneys in a manner that increases toxicity. However, the patient's overall health status should be stable before injection.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic extracts does not involve the CYP450 system.

Elderly Patients

Geriatric patients may have a reduced skin response to testing. Caution is advised in patients with co-morbid cardiovascular disease, as they may be less able to tolerate the hemodynamic stress of a systemic reaction or the use of epinephrine (adrenaline).

Verbascum Thapsus Whole extracts are for professional use only and must never be self-administered by the patient at home.

• Administration Site: Subcutaneous injection in the posterior aspect of the upper arm.
• Observation Period: Patients must remain in the clinical setting for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins and render the extract ineffective or dangerous.
• Site Rotation: Injection sites should be rotated between the left and right arms to minimize local tissue irritation.

In immunotherapy, a missed dose requires a 'step-back' in the dosage schedule to ensure safety:

• Missed 1–2 weeks: Repeat the last tolerated dose.
• Missed 3–4 weeks: Reduce the dose by one or two increments.
• Missed >4 weeks: Consult the allergist; the build-up phase may need to be restarted from a much lower concentration.

An overdose in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level.

• Signs: Rapid onset of hives (urticaria), swelling of the throat (angioedema), wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults), followed by antihistamines, corticosteroids, and oxygen. The patient should be transported to an emergency department for observation.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing treatment with Verbascum Thapsus Whole will experience some form of local reaction. These are generally not dangerous but indicate the immune system is responding to the allergen.

• Local Redness (Erythema): A red patch at the injection site that usually appears within minutes and fades within a few hours.
• Local Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal response.
• Itching (Pruritus): Intense itching at the site of injection or testing.
• Tenderness: The injection site may feel sore or 'bruised' for 24–48 hours.

• Large Local Reactions (LLR): Swelling that exceeds 5 cm in diameter. This may require a dose adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy injection.
• Headache: Mild to moderate tension-type headaches.
• Nasal Congestion: A temporary 'flare' of allergic rhinitis symptoms shortly after the injection.

• Systemic Urticaria: Hives appearing on parts of the body away from the injection site.
• Generalized Pruritus: Itching of the palms, soles of the feet, or scalp, which can be an early warning sign of a systemic reaction.
• Vasovagal Syncope: Fainting due to needle anxiety rather than the extract itself.

> Warning: Stop taking Verbascum Thapsus Whole and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Angioedema: Swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Sudden wheezing, chest tightness, or difficulty breathing. This is particularly common in patients with poorly controlled asthma.
• Hypotension: A sharp drop in blood pressure leading to dizziness, 'tunnel vision,' or fainting.
• Cardiac Arrest: In extremely rare cases of severe anaphylaxis, the heart may stop beating.
• Cyanosis: A bluish tint to the skin or lips indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Verbascum Thapsus Whole extracts. Unlike corticosteroids or other immunosuppressants, allergenic extracts do not cause organ damage over time. The primary long-term risk is the development of a new sensitivity to a different component of the extract, though this is rare. Most patients find that after 3–5 years of treatment, they remain symptom-free for many years after discontinuation.

While Verbascum Thapsus Whole may not have a specific individual black box warning, all Allergenic Extracts as a class carry a general warning regarding Anaphylaxis:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Do not administer to patients with unstable or severe asthma.
• Patients must be observed for at least 30 minutes in a facility equipped to treat anaphylaxis.
• Patients should be informed of the signs and symptoms of severe allergic reactions and instructed to seek immediate medical care if they occur after leaving the clinic.

Report any unusual symptoms to your healthcare provider.

Verbascum Thapsus Whole is a potent biological substance. It is not a medication in the traditional sense but an immunological modifier. Its use requires a high degree of clinical vigilance. Patients must be 'clinically stable' on the day of injection. If a patient is experiencing an asthma flare-up or a severe upper respiratory infection, the injection should be postponed.

No specific FDA black box warning exists specifically for the Verbascum Thapsus species alone; however, it is governed by the class-wide black box warning for all allergenic extracts. This warning emphasizes that these products should only be used by physicians experienced in the diagnosis and treatment of allergic diseases and that they are potentially fatal if administered incorrectly or to highly sensitive individuals.

• Anaphylaxis Risk: This is the primary concern. Anaphylaxis can occur even in patients who have previously tolerated the same dose. Epinephrine must always be immediately available.
• Asthma Status: Patients with uncontrolled asthma (FEV1 < 70% of predicted) are at a significantly higher risk for fatal systemic reactions. Asthma must be stabilized before beginning or continuing Verbascum Thapsus Whole therapy.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This includes ophthalmic beta-blocker eye drops.
• Injection Technique: Accidental intravenous injection can cause immediate, severe systemic reactions. Aspiration before injection is mandatory to ensure the needle is in the subcutaneous tissue.

• Peak Flow/Spirometry: Patients with a history of asthma should have their lung function checked before each injection.
• Visual Inspection of the Site: The clinician must measure and record any local reactions (wheal/erythema) from the previous injection before administering the next dose.
• 30-Minute Wait: This is a non-negotiable monitoring requirement. Most fatal reactions occur within 20 minutes of injection.

Verbascum Thapsus Whole does not directly cause sedation or cognitive impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol consumption should be avoided for several hours before and after an injection. Alcohol causes vasodilation, which can theoretically increase the rate of allergen absorption and heighten the risk of a systemic reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal' syndrome associated with stopping Verbascum Thapsus Whole. However, stopping prematurely (e.g., after only 1 year) usually results in the return of allergy symptoms within a few months.

> Important: Discuss all your medical conditions with your healthcare provider before starting Verbascum Thapsus Whole.

• Beta-Adrenergic Blockers (Beta-Blockers): This includes drugs like carvedilol, atenolol, and timolol. The interaction is not with the extract itself, but with the rescue medication (epinephrine). Beta-blockers prevent epinephrine from binding to its receptors, potentially leading to 'epinephrine-resistant' anaphylaxis. This combination is generally considered an absolute contraindication for elective immunotherapy.

• ACE Inhibitors: Drugs like lisinopril or enalapril may increase the risk of severe systemic reactions and may interfere with the body's natural compensatory mechanisms during an allergic event.
• MAO Inhibitors (MAOIs): Drugs like phenelzine or selegiline can potentiate the effects of epinephrine, leading to a hypertensive crisis if epinephrine is needed to treat a reaction.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs (e.g., amitriptyline) can increase the cardiovascular effects of epinephrine.

• Antihistamines: While not dangerous, antihistamines (e.g., cetirizine, loratadine) will suppress the 'wheal and flare' response during skin testing, leading to false-negative results. These must be discontinued 3–7 days before diagnostic testing.
• H2 Blockers: Drugs like famotidine can also slightly interfere with skin test results.
• Systemic Corticosteroids: Long-term use of high-dose prednisone may suppress the immune response to the extract, potentially reducing the efficacy of immunotherapy.

There are no direct food interactions with Verbascum Thapsus Whole. However, patients with 'Oral Allergy Syndrome' (OAS) may experience cross-reactivity between certain weeds and foods (e.g., melon, banana). If a patient is experiencing an OAS flare-up, they should inform their doctor before receiving an injection.

• St. John's Wort: May theoretically affect the sensitivity of the skin or the immune response, though clinical data is lacking.
• Astragalus/Echinacea: These immune-stimulating herbs could theoretically interfere with the desensitization process of immunotherapy.

• Skin Testing: As mentioned, antihistamines and some antidepressants will interfere with the accuracy of skin prick tests.
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels during the build-up phase, which should not be misinterpreted as a worsening of the allergic condition.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Verbascum Thapsus Whole must NEVER be used in the following circumstances:

1. 1Severe/Uncontrolled Asthma: If the patient's asthma is not well-managed or if they have had a recent exacerbation requiring hospitalization. The risk of a fatal bronchospasm during a systemic reaction is too high.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The heart may not be able to handle the stress of anaphylaxis or the administration of epinephrine.
3. 3Hypersensitivity to Diluent Components: If a patient is allergic to phenol (a preservative) or human serum albumin (a stabilizer) used in the extract formulation.
4. 4Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.

These conditions require a careful risk-benefit analysis by the allergist:

• Autoimmune Diseases: There is a theoretical risk that stimulating the immune system with allergenic extracts could worsen conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients undergoing active chemotherapy or with certain types of cancer may have unpredictable immune responses.
• Severe Atopic Dermatitis: May make the interpretation of skin tests impossible.
• Eosinophilic Esophagitis (EoE): Some evidence suggests that subcutaneous immunotherapy might trigger or worsen EoE in susceptible individuals.

Patients allergic to Verbascum Thapsus may show cross-reactivity with other members of the Scrophulariaceae family. While less common, some cross-reactivity with pollens from the Compositae family (like Ragweed) has been observed in clinical practice. Your doctor will use this information to design a safe and effective 'cocktail' of extracts if you are allergic to multiple substances.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Verbascum Thapsus Whole.

• Pregnancy Category: Not formally assigned by the FDA, but generally considered cautiously.
• Risk Summary: Immunotherapy with Verbascum Thapsus Whole should not be started during pregnancy because the risk of a systemic reaction (and subsequent fetal hypoxia) is highest during the build-up phase.
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the therapy can often be continued, as the risk of a reaction is much lower. However, the dose is typically not increased during pregnancy.
• Teratogenicity: There is no evidence that allergenic extracts cause birth defects.

Verbascum Thapsus Whole is considered safe for use during breastfeeding. The allergenic proteins are processed locally and are not expected to pass into breast milk in any significant quantity. The infant is not at risk of sensitization through breast milk.

• Approved Age: Generally recommended for children 5 years of age and older.
• Considerations: Children must be able to cooperate with the injection process and, more importantly, be able to describe early symptoms of a reaction (e.g., 'my throat feels funny' or 'my palms are itchy').
• Growth: There is no evidence that allergenic extracts affect growth or development.

• Cardiovascular Risk: Older adults are more likely to have underlying heart disease, which increases the risk of complications if a systemic reaction occurs.
• Skin Reactivity: Skin test reactivity decreases with age, which may lead to false-negative results in patients over 65.
• Polypharmacy: Older patients are more likely to be on medications (like beta-blockers or ACE inhibitors) that complicate immunotherapy safety.

No dosage adjustments are required. The proteins in Verbascum Thapsus Whole are broken down into amino acids and peptides by cellular proteases and are not dependent on renal filtration for clearance.

No dosage adjustments are required. The liver's metabolic capacity does not affect the safety or efficacy of allergenic extracts.

> Important: Special populations require individualized medical assessment.

Verbascum Thapsus Whole contains a complex mixture of proteins that serve as allergens. Upon subcutaneous injection, these proteins are captured by Dendritic Cells (antigen-presenting cells). These cells migrate to the lymph nodes and present the allergen fragments to Naive T-Cells. In an allergic individual, this usually results in Th2 cell activation. However, the controlled, repeated exposure provided by immunotherapy induces the formation of Regulatory T-Cells (Tregs). These Tregs secrete IL-10 and TGF-beta, which suppress allergic inflammation and signal B-cells to switch from producing IgE to IgG4. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) are more effective at inducing long-term tolerance than low doses.
• Onset of Effect: Diagnostic skin tests work within 15–20 minutes. Therapeutic effects (symptom reduction) typically take 6 to 12 months of consistent treatment to become apparent.
• Duration of Effect: After a full 3–5 year course, the immunological 'memory' and tolerance can last for 5–10 years or longer.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | Minimal (processed by APCs) |

| Half-life (Proteins) | < 24 hours |

| Tmax (Systemic Absorption) | 30–60 minutes |

| Metabolism | Proteolysis (cellular) |

| Excretion | Lymphatic/Cellular Degradation |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides extracted from the whole plant of Verbascum thapsus.
• Solubility: Highly soluble in aqueous solutions (saline).
• Stability: Sensitive to heat and light; requires refrigeration at 2–8°C.

Verbascum Thapsus Whole is a member of the Allergenic Extract therapeutic class. It is specifically categorized as a Standardized Chemical Allergen [EPC] when manufactured to specific potency standards, although many versions remain non-standardized. It is related to other plant-based extracts like Ragweed, Timothy Grass, and Oak extracts.